3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1/2
4
Phase 3
3
Phase 2/3
2
Phase 1
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Conditions
Melanoma, Cutaneous Malignant
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
129
pembrolizumab
124
Cisplatin
114
Paclitaxel
102
Gemcitabine
85
Specimen Handling
80
Magnetic Resonance Spectroscopy
80
Docetaxel
70
Dexamethasone
59
Cyclophosphamide
59
Pemetrexed
55
Bevacizumab
54
durvalumab
53
Doxorubicin
52
Radiotherapy
49
Capecitabine
49
Radiation
47
Oxaliplatin
47
Fluorouracil
47
Rituximab
42
Leucovorin
42
Vincristine
41
Lenalidomide
40
Etoposide
38
Letrozole
36
atezolizumab
35
Nivolumab
35
Prednisone
31
Bortezomib
31
130-nm albumin-bound paclitaxel
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
relatlimab
×
90 days
×
Clear all
NCT05625399
2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3
Active not recruiting
579 enrolled
NCT06743126
2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled
NCT06561386
2026-05-20
RELATIVITY1093
Bristol-Myers Squibb
Phase 3
Recruiting
1,000 enrolled